• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why ORIC Pharmaceuticals Shares Are Trading Higher By Around 46%; Here Are 27 Stocks Moving Premarket

    12/22/22 6:17:31 AM ET
    $ARTL
    $AVYA
    $CORZ
    $GLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $ARTL alert in real time by email

     

    Don’t forget to check out our premarket coverage here .


    Losers

    • Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS) fell 16% to $0.1054 in pre-market trading after jumping 29% on Wednesday. Powerbridge Technologies recently announced the strategic acquisition of DTI Group.
    • Helius Medical Technologies, Inc. (NASDAQ:HSDT) shares fell 14.7% to $0.21 in pre-market trading. Maxim Group recently initiated coverage on the stock with a Buy rating and a $1 price target.
    • Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) fell 8.8% to $0.4202 in pre-market trading after jumping over 40% on Wednesday.
    • Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) fell 8.4% to $1.74 in pre-market trading after the company reported topline results from Phase 2 proof-of-concept study of LX9211 in postherpetic neuralgia. The company said primary endpoint was not met.
    • Venus Concept Inc. (NASDAQ:VERO) fell 7.8% to $0.2748 in pre-market trading. Venus Concept shares jumped 18% on Wednesday after the company received an FDA 510(k) clearance to market its AI.ME next-generation robotic technology for fractional skin resurfacing.
    • Opendoor Technologies Inc. (NASDAQ:OPEN) shares fell 7.8% to $1.05 in pre-market trading after dropping around 10% on Wednesday.
    • Otonomy, Inc. (NASDAQ:OTIC) shares fell 7.6% to $0.0801 in pre-market trading. Otonomy recently announced plans to liquidate and dissolve following an orderly wind down of operations.
    • Avaya Holdings Corp. (NYSE:AVYA) fell 7.4% to $0.2077 in pre-market trading after jumping around 8% on Wednesday.
    • Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) fell 7.3% to $0.3101 in pre-market trading. Vallon Pharmaceuticals and GRI Bio recently announced they entered into a merger agreement.
    • Artelo Biosciences, Inc. (NASDAQ:ARTL) fell 6.5% to $2.92 in pre-market trading.
    • Micron Technology, Inc. (NASDAQ:MU) fell 2.9% to $49.70 in pre-market trading after the company reported downbeat results for its first quarter and issued weak earnings forecast for the second quarter. The company also announced plans to lay off 10% of its workforce next year.

    Read Next: CarMax, Micron And 3 Stocks To Watch Heading Into Thursday

    Get the next $ARTL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARTL
    $AVYA
    $CORZ
    $GLMD

    CompanyDatePrice TargetRatingAnalyst
    Core Scientific Inc.
    $CORZ
    3/3/2026$23.00Hold → Buy
    Needham
    Micron Technology Inc.
    $MU
    2/17/2026$380.00 → $450.00Buy
    Needham
    Micron Technology Inc.
    $MU
    1/23/2026$350.00 → $500.00Buy
    HSBC Securities
    Micron Technology Inc.
    $MU
    1/22/2026Outperform
    William Blair
    Micron Technology Inc.
    $MU
    1/20/2026$300.00 → $450.00Buy
    TD Cowen
    Micron Technology Inc.
    $MU
    1/16/2026$275.00 → $450.00Overweight
    Barclays
    Micron Technology Inc.
    $MU
    1/15/2026$425.00Outperform
    RBC Capital Mkts
    Micron Technology Inc.
    $MU
    1/7/2026$300.00 → $400.00Buy
    UBS
    More analyst ratings

    $ARTL
    $AVYA
    $CORZ
    $GLMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

    THE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin on people with type 1 diabetes will be delivered as a short oral presentation tomorrow, March 12, during the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The congress is being held March 11-14, 2026, in Barcelona, Spain. "Recognizing that a patient's kidney function can impact the efficacy of SGLT inhibitors, we conducted this post hoc analysis of clinical data from two identically-des

    3/11/26 8:00:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadillac Formula 1® Team Joins Forces with Core Scientific as Official Data Center Partner

    Core Scientific and Cadillac Formula 1® Team Announce a Multi-Year Global Partnership Core Scientific, Inc. (NASDAQ:CORZ) ("Core Scientific" or the "Company"), a leader in digital infrastructure for high-density colocation, and Cadillac Formula 1® Team have announced a multi-year global partnership, naming Core Scientific as the team's Official Data Center Partner. Core Scientific will play a central role in advising and shaping the team's data center infrastructure in its new U.S. headquarters, currently under construction in Indianapolis, Indiana. Through this partnership, Core Scientific will provide strategic consulting, architectural guidance and optimization expertise to ensure th

    3/10/26 8:00:00 AM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    $ARTL
    $AVYA
    $CORZ
    $GLMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weiss Eric Stanton bought $101,700 worth of shares (7,000 units at $14.53), increasing direct ownership by 3% to 252,262 units (SEC Form 4)

    4 - Core Scientific, Inc./tx (0001839341) (Issuer)

    3/10/26 4:08:53 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    SVP, Human Resources Mcdermott Wendy converted options into 224,406 shares and covered exercise/tax liability with 68,107 shares, increasing direct ownership by 128% to 277,945 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    3/3/26 7:20:59 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Partnerships & Corp Strat Martens Rachel Yap converted options into 67,090 shares and covered exercise/tax liability with 35,826 shares (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    3/3/26 7:20:20 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $AVYA
    $CORZ
    $GLMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weiss Eric Stanton bought $101,700 worth of shares (7,000 units at $14.53), increasing direct ownership by 3% to 252,262 units (SEC Form 4)

    4 - Core Scientific, Inc./tx (0001839341) (Issuer)

    3/10/26 4:08:53 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/27/26 8:33:21 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $147,000 worth of shares (100,000 units at $1.47), increasing direct ownership by 6% to 1,904,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/25/26 7:00:27 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $AVYA
    $CORZ
    $GLMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Core Scientific upgraded by Needham with a new price target

    Needham upgraded Core Scientific from Hold to Buy and set a new price target of $23.00

    3/3/26 10:31:14 AM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Needham reiterated coverage on Micron with a new price target

    Needham reiterated coverage of Micron with a rating of Buy and set a new price target of $450.00 from $380.00 previously

    2/17/26 7:06:48 AM ET
    $MU
    Semiconductors
    Technology

    HSBC Securities reiterated coverage on Micron with a new price target

    HSBC Securities reiterated coverage of Micron with a rating of Buy and set a new price target of $500.00 from $350.00 previously

    1/23/26 10:28:05 AM ET
    $MU
    Semiconductors
    Technology

    $ARTL
    $AVYA
    $CORZ
    $GLMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

    Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

    5/30/23 10:02:49 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $AVYA
    $CORZ
    $GLMD
    SEC Filings

    View All

    Core Scientific Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Core Scientific, Inc./tx (0001839341) (Filer)

    3/6/26 4:13:50 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Artelo Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    3/6/26 8:30:28 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Lexicon Pharmaceuticals Inc.

    10-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)

    3/5/26 4:50:45 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $AVYA
    $CORZ
    $GLMD
    Leadership Updates

    Live Leadership Updates

    View All

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Opendoor Names President and CFO to Accelerate Next Chapter

    MIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. (NASDAQ:OPEN) today announced two executive appointments designed to accelerate the Company's next phase of growth: President from the fintech frontier, and CFO promoted from within after an extensive external search. Accelerating our next chapter Lucas Matheson joins as President on December 22, 2025. Matheson most recently served as CEO of Coinbase Canada and previously spent five years at Shopify leading acceleration finance (M&A), strategic expansion, corporate financial planning & analysis and various operational roles. At Opendoor, Matheson will oversee Corporate Development, Financial Planning & Analysis, and em

    12/15/25 7:00:00 AM ET
    $OPEN
    Real Estate
    Finance

    BluSky AI Inc. Appoints Riley Cooney as Corporate Development and Strategy Officer

    Salt Lake City Utah, Dec. 09, 2025 (GLOBE NEWSWIRE) -- BluSky AI Inc. (OTCID: BSAI), a leading developer of prefabricated modular AI infrastructure and Neocloud GPU-as-a-Service infrastructure, proudly announces the appointment of Riley Cooney as its Corporate Development and Strategy Officer. Cooney is a well-respected FP&A and strategic finance executive whose experience includes leadership through a $4B IPO in BTC and Hyperscale infrastructure. Riley has advised on AI and HPC data-center strategy, serving global institutional and Wall Street clients over the past two years. During his five years at Core Scientific (NASDAQ:CORZ), Riley helped scale revenue 24× while growing power capaci

    12/9/25 1:37:56 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    $ARTL
    $AVYA
    $CORZ
    $GLMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

    SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    12/9/24 9:33:20 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

    SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    11/14/24 4:26:14 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Galmed Pharmaceuticals Ltd.

    SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

    11/14/24 12:24:34 PM ET
    $GLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $AVYA
    $CORZ
    $GLMD
    Financials

    Live finance-specific insights

    View All

    Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

    Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM  Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments.  "

    3/5/26 6:59:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Core Scientific Announces Fourth Quarter Fiscal Year 2025 Results

    Key Highlights New Top-market Site: Announced an agreement to expand into Hunt County, Texas, which is expected to support ~430 MW of gross power capacity, with an approved ERCOT interconnection ramp schedule. Power Expansion at Existing Locations: Increased gross power capacity by ~300 MW across Dalton, Georgia and Pecos, Texas. Continued Execution on CoreWeave Contract: To date, energized ~350 MW of power and remain on track to deliver ~590 MW by early 2027. Core Scientific, Inc. (NASDAQ:CORZ), a leader in digital infrastructure for high-density colocation services, today announced financial results for the fourth quarter of 2025. "We're now past the halfway point on our e

    3/2/26 4:10:00 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

    THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast w

    2/26/26 8:30:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care